Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zanubrutinib + Rituximab vs Bendamustine + Rituximab in Untreated Mantle Cell Lymphoma
NCT04002297Phase 3Active, not recruiting
- Sponsor
- BeOne Medicines
- Start
- Aug 2019
- Primary completion
- Apr 2026
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 22
01
Overview
A Phase 3 trial of zanubrutinib in mantle cell lymphoma (MCL), sponsored by BeOne Medicines. Started Aug 2019; status: active, not recruiting.
02
Drugs
zanubrutinib
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT04002297.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04002297.